Amyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. by Russell, CL et al.
Amyloid-b Acts as a Regulator of Neurotransmitter
Release Disrupting the Interaction between
Synaptophysin and VAMP2
Claire L. Russell1, Sophia Semerdjieva1, Ruth M. Empson1,2, Brian M. Austen3, Philip W. Beesley1,
Pavlos Alifragis1*
1 School of Biological Sciences, Royal Holloway University London, Surrey, United Kingdom, 2Department of Physiology, University of Otago School of Medical Sciences,
Dunedin, New Zealand, 3Neurodegeneration Unit, Basic Medical Sciences, St George’s, University of London, Cranmer Terrace, London, United Kingdom
Abstract
Background: It is becoming increasingly evident that deficits in the cortex and hippocampus at early stages of dementia in
Alzheimer’s disease (AD) are associated with synaptic damage caused by oligomers of the toxic amyloid-b peptide (Ab42).
However, the underlying molecular and cellular mechanisms behind these deficits are not fully understood. Here we
provide evidence of a mechanism by which Ab42 affects synaptic transmission regulating neurotransmitter release.
Methodology/Findings: We first showed that application of 50 nM Ab42 in cultured neurones is followed by its
internalisation and translocation to synaptic contacts. Interestingly, our results demonstrate that with time, Ab42 can be
detected at the presynaptic terminals where it interacts with Synaptophysin. Furthermore, data from dissociated
hippocampal neurons as well as biochemical data provide evidence that Ab42 disrupts the complex formed between
Synaptophysin and VAMP2 increasing the amount of primed vesicles and exocytosis. Finally, electrophysiology recordings in
brain slices confirmed that Ab42 affects baseline transmission.
Conclusions/Significance: Our observations provide a necessary and timely insight into cellular mechanisms that underlie
the initial pathological events that lead to synaptic dysfunction in Alzheimer’s disease. Our results demonstrate a new
mechanism by which Ab42 affects synaptic activity.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder. The brain of AD patients is characterised by neuronal
loss, the presence of extracellular senile plaques comprised of b-
amyloid peptide (Ab) and intracellular neurofibrillary tangles
(NFT) consisting of aggregates of hyperphosphorylated tau protein
[1]. Ab is derived from the proteolytic cleavage of the amyloid
precursor protein (APP) [2] and the identification of Ab as the
major component of senile plaques led to the hypothesis that its
extracellular deposition could be a key factor in the progression of
AD [3]. Despite a clear association between Ab build up and
cognitive decline, [4,5,6,7,8] a correlation between plaque de-
position and the severity of dementia, could not be established. On
the contrary, the cognitive decline appears to be underlined by
defects in synaptic plasticity and by loss or dysfunction of synapses
[9,10,11] that precede Ab deposition and NFT formation
[12,13,14]. It is now believed that small soluble Ab oligomers,
are responsible for early synaptic changes [15].
Although it is well established that Ab affects long term
potentiation (LTP) and long term depression (LTD), the causal
mechanisms are still elusive [16]. NMDAR dependent LTP in the
hippocampus is blocked upon application of Ab [7,17,18].
Intriguingly though, at low concentrations Ab induces LTP
possibly through a-7 nicotinic acetylcholine receptors [19].
Furthermore, Ab induces LTD and excitotoxicity mediated by
NMDARs receptors [20]. The importance of glutamate signalling
via NMDARs as a causative event of dementia in AD is further
demonstrated, by findings that memantine -a low affinity
antagonist for NMDARs- results in behavioural improvement in
AD model transgenic mice and is used as treatment of moderate
AD [21,22,23]. This raises the possibility that the effects of Ab
could be due to an agonist action on NMDARs [24]. However, it
is not fully established whether these effects are mediated directly
through NMDARs. On the contrary evidence suggests that high
concentration or prolonged exposure to Ab42 is required to
establish a direct effect on AMPA or NMDA receptors
[10,25,26,27]. Thus, it is unlikely that AMPA- and NMDA-
receptors are directly affected at the earliest stages of AD
pathology. Since there is no conclusive evidence of a direct
interaction between Ab and NMDARs, proposals such as
a reduction in glutamate uptake or an increase of glutamate
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e43201
release have been put forward to explain these findings
[19,28,29,30,31,32,33], but the cellular mechanisms underlying
these defects are not clearly understood.
Here, we investigated cellular and molecular mechanisms by
which Ab induces synaptic toxicity. We show that administration
of Ab42 peptides to mature hippocampal neurons is followed by its
internalisation. Subsequently, Ab42 is detected at presynaptic
terminals, where it can interact with Synaptophysin (Syp). We
show that this interaction disrupts the Syp/VAMP2 complex and
that this disruption could contribute to an expansion of the primed
synaptic vesicle pool and of baseline neurotransmission.
Materials and Methods
Hippocampal Cell Culture
All animal experiments were performed according to Home
Office regulations in appliance with the Animals Scientific Act
1986. Primary cultures of CA3-CA1 hippocampal neurons were
prepared from E18 Sprague Dawley rat embryos. The experi-
ments were performed in mature (21–28 days in vitro (DIV))
cultures. Neurons were seeded on poly-D-lysine (100 mg/ml in
0.1 M borate buffer) and laminin (5 mg/ml in PBS) coated
coverslips at a density of 75,000 cells per coverslip and were
maintained at 37uC, 5% CO2 in Neurobasal media, supplemented
with B27, L-glutamine (0.5 mM) and 100 units/ml penicillin/
streptomycin.
Immunocytochemistry
Hippocampal cultures were rinsed once with PBS and fixed
with 4% paraformaldehyde (PFA) in PBS. Fixed neurons were
washed, permeabilised with 0.1% Tween-20 and 5% horse
serum in PBS for 45 min at room temperature, and were
incubated with primary antibodies overnight at 4uC. After
washing, cells were incubated for two hours at room temper-
ature with Alexa Fluor 488 or Alexa Fluor 555 (Molecular
Probes, UK). Primary antibodies used were: Anti-Ab 6E10 (ID
Labs Ontario, Canada and Abcam Cambridge, UK), Anti-
NR2A/B (Millipore Watford, UK). All other primary antibodies
were supplied by Abcam. For internalisation assays, fixed cells
were incubated with 6E10 followed by Alexa Fluor 488, then
postfixed in 4% PFA for two minutes. Cells were re-incubated
with 6E10 in the presence of 0.1% Tween-20, followed by the
secondary antibody Alexa Fluor 555. In all experiments, the
cells were rinsed, mounted with ProLong reagent, and visualised
on a spin disc confocal system (CARV from Digital Imaging
Solutions) with an EM-CCD camera (Rolera/QI Cam 3500)
mounted in an Olympus X71 microscope with a 1006
objective, using Image Pro 6.0 software. High magnification
inlets were produced using Adobe Photoshop.
FM1-43FX Labelling
Following exposure to 50 nM of Ab for 20 min and 2 hrs of
recovery, 5 mM of FM1-43FX dye (prepared in HBSS warmed to
37uC) was applied to the cells for 5 min, followed by application of
a hypertonic 500 mM sucrose solution in HBSS with 5 mM FM1-
43FX. After 5 min the sucrose solution was replaced with the
original FM1-43FX solution for 15 min. The cells were then
washed twice for 15 min in HBSS to remove un-incorporated dye
and were subsequently fixed in 4% paraformaldehyde. Cells were
kept in the dark until utilised.
Protein Extracts and Immunoprecipitation
Hippocampi were isolated from the brains of two juvenile
Sprague Dawley rats of either sex (weighing between 90 g and
140 g) and homogenized in 1 mL lysis buffer (25 mM HEPES
pH 7.5, 150 mM NaCl, 1% NP-40, 10 mM MgCl2, 1 mM
EDTA, 2% Glycerol), containing a protease cocktail inhibitor
(Roche, UK). Protein G DynabeadsH (25 mL) (Invitrogen, UK)
were incubated with 5 mg of the precipitating monoclonal
antibody for one hour at 4uC. Scrambled peptide and Ab42 were
diluted in 100 ml hippocampal protein extracts (,7 mg/ml) at
a final concentration of 100 mM and the mix was incubated with
the antibody bound DynabeadsH at 4uC for 4 hrs. Samples were
boiled for 5 min to elute bound proteins, which were then
analysed by SDS-PAGE.
Immunoblot
Proteins were separated on NuPage 4–12% Bis-Tris gels at
200 V and transferred to nitrocellulose membrane at 100 V for
1 hr at 4uC in transfer buffer (200 mM Glycine, 25 mM Tris Base
Figure 1. Identification of proteins interacting with Ab by
candidate approach. (a) Western blotting with primary antibodies
against synaptic markers detected specific proteins in the starting
material at their expected molecular weights. Only the primary
antibody against Syp detected a specific protein in the fraction eluted
from the Ab affinity column. (b) Oligomerisation state of Ab42
compared to Ab40 revealed by western blotting. Monomeric Ab
peptides can be seen as a band at 4 kDa. Only Ab42 displayed visible
low molecular weight aggregates.
doi:10.1371/journal.pone.0043201.g001
Amyloid-Beta and Synaptic Activity
PLOS ONE | www.plosone.org 2 August 2012 | Volume 7 | Issue 8 | e43201
20% Methanol). Blots were blocked with 5% nonfat dry milk in
Tris-buffered saline (50 mM Tris Base, 150 mM NaCl) containing
0.1% Tween 20, pH 7.5, for 1 hr and incubated overnight at 4uC
with primary antibody (1:250) and 2 hrs with HRP-conjugated
secondary antibody (1:1000). Membranes were developed with
SuperSignal chemiluminescence kit according to instructions.
Hippocampal Slice Preparation
Field potential recordings were made from ventral sections of
postnatal day 32–42 Sprague Dawley rats of either sex. Rats were
deeply anesthetised by halothane prior to decapitation, and the
brain rapidly removed and submerged in oxygenated (95% O2,
5%CO2) artificial cerebrospinal fluid (aCSF) containing
135 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 1 mM MgCl2,
10 mM Glucose and 26 mM NaHCO3. The brain was hemi-
sected, and ventral sections (400 mm thick) prepared in aCSF on
a Vibroslice (Campden Instruments Ltd). Slices were transferred
and submerged in a holding chamber of continually oxygenated
aCSF and left to recover for at least one hour. Ab42, Ab40 and
scrambled Ab peptide were added to the chamber to treat slices
for 45 minutes prior to field EPSP recordings. Lyophilised fraction
from 7PA2 cell media containing nanomolar amounts of Ab
oligomers was re-suspended in 100 ml aCSF in the tissue chamber
to treat hippocampal slices for 45 min.
Electrophysiology
Recordings of field excitatory post synaptic potentials (fEPSPs)
were made from the stratum radiatum in the CA1 region of the
hippocampus using low resistance glass electrodes, in response to
stimulation of the Schaffer collateral commissural pathway using
a monopolar borosilicate glass electrode driven by a constant
voltage stimulator (Digitimer) DC recordings were amplified using
an AxoClamp2A (Molecular Devices) and a Neurolog NL104
(Digitimer Ltd) and signals filtered at 3 kHz prior to digitisation
with a CED1401. Experiments were controlled using Signal 2
(CED Ltd) running on a connected PC. Electrodes were positioned
just below the tissue surface (liquid interface setup) and slices were
left to stabilise for 20 min. Input/output curves (or stimulation
responses) were recorded, and the 10–90% slope measured, from
a stimulus ranging from 10 V to 70 V with 3 successive events at
each input level, 30 sec apart. To detect concentration dependent
changes in neurotransmitter release, fEPSPs were initially evoked
at 50 V with low frequency at 0.033 Hz in the presence of
different concentrations of Ab42. For LTP recordings, a stable
baseline was maintained for 25 min at 50% of the maximum
fEPSP response, and LTP was induced by high frequency
stimulation (HFS) consisting of three trains of 100 Hz, 10 sec
apart. Potentiated synaptic response was subsequently recorded
with low frequency stimulation every 30 sec for at least 90 min.
Figure 2. Representative images showing the dynamics of Ab42 internalisation by sequential immuno-labelling. Mature hippocampal
neurons incubated with Ab42 for 20 min were left to recover for 15 min, 2 hrs and 4 hrs. (a) Labelling for external (red) and internalised (green) Ab42
after 15 min recovery period. Arrows at high magnification images of boxed area (right) point at examples of overlapping staining. A reduction in co-
labelling was observed after 2 hrs (b) or 4 hrs (c) recovery. Arrowheads at high magnification images of boxed area (right) show examples of external
and arrows of internalised Ab42. (d) Quantification of the extent of co-localisation shows a high degree of co-localisation at 15 min recovery
(M=0.9260.07, n = 6) compared to 2 hrs (M=0.6460.07, student t-test ** = 0.0006, n = 10) and 4 hrs (M= 0.7060.08, student t-test * = 0.0021, n = 8)
of recovery. Scale bar = 10 mm.
doi:10.1371/journal.pone.0043201.g002
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Synthetic Ab Peptides
Ab42 (American Peptide USA) was prepared as described
previously [34] and stored in 0.1 M Tris pH7.4 at a stock
concentration of 100 mM at220uC. Neurons were incubated with
50 nM of peptide for 20 min. Following treatment, the media was
replaced with fresh supplemented Neurobasal and the cells were
left to recover for the specified times.
Cell-Derived Ab
7PA2 cells (a kind gift from D.M. Walsh, University College
Dublin) [35], are a CHO cell line stably expressing human APP751
carrying the V717F AD causing mutation. Cell cultures of 90%
confluency were washed with serum free DMEM followed by
incubation for 18 hrs in serum free DMEM. The conditioned
medium was collected, cleared of cells by centrifugation (1346gav
for 10 mins), and protease inhibitors were added to the
supernatant. Ab oligomers were separated by size exclusion
Figure 3. Representative images demonstrating presynaptic localisation of Ab42 (green) in mature hippocampal neurons,
incubated with Ab42 for 20 min and left to recover for various time points. After 15 min recovery, Ab42 and Syp (a) or Ab42 and VAMP2 (c)
labelling is distinct and often juxtaposed (as detailed in high magnifications of boxed areas (right), n = 15). After 2 hrs of recovery co-localisation of
Ab42 with Syp (b) and VAMP2 (d) can be observed (n = 39 for each condition). Arrows at high magnification images of boxed area (right) point at
examples of Syp (b) or VAMP2 (d) positive synaptic contacts that are also positive for Ab42. Bracket in high magnification images of boxed area (d)
shows diffuse VAMP2 staining evident after the 2 hrs recovery period. After 2 hrs of recovery Ab42 is often juxtaposed to NMDAR (e) (n = 18) even
after depolarisation (f) (n = 10). Arrows in high magnification images of boxed area point at examples of Ab42 juxtaposed to NMDAR. Scale
bar = 10 mm.
doi:10.1371/journal.pone.0043201.g003
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chromatography as described [36]. Briefly, 1 ml of concentrated
CM from each cell line was injected onto a Superdex 75 10/30
HR column attached to a AKTA HPLC system (Amersham) and
eluted at a 0.4 mL/min. flow rate with 50 mM ammonium
acetate (pH 8.5). The eluent was monitored at 280 nm and
230 nm and collected in fractions (0.5 ml). 50 ml of each fraction
was used in a double ELISA assay to determine Ab oligomer
content as previously described [37]. The remaining fractions
containing Ab peptides were pooled together and used to treat
hippocampal slices.
Results
Ab Interacts with Synaptophysin
To examine the underlying mechanisms behind Ab42 induced
excitotoxicity, we designed a proteomic screen, based on an
affinity column of Ab42, to identify synaptic proteins from
hippocampal extracts that bind to the peptide. Bound proteins
were first characterised by a candidate approach using antibodies
against specific synaptic proteins to probe Western blots. Among
various proteins examined, Syp, a protein present at synaptic
vesicles (SV) was detected at high levels (fig. 1a). Antibodies against
additional pre-synaptic markers, such as synaptosomal-associated
protein 25 (SNAP25) and vesicle associated protein 2 (VAMP2 or
synaptopbrevin 2) failed to detect any protein in the eluted
fractions. In addition, antibodies against postsynaptic proteins,
such as the post synaptic density protein PSD95 were also used
and again no bands were observed (fig. 1a). These results suggest
that Syp is a strong candidate to be a specific interacting partner of
Ab42.
Internalisation of Ab42 in Neurons
We then explored the significance of this interaction in
dissociated neurons. For this interaction to occur in vivo, Ab42
should be present inside the neurons, at the presynaptic terminal.
Ab42 accumulates intracellularly via two possible avenues; either it
builds up because part of the intracellular pool is not secreted, or
extracellular Ab42 is internalised by neurons [38]. Thus, we
developed an internalisation assay to investigate the dynamics and
the subcellular distribution of externally administered synthetic
Ab42. Synthetic Ab42 is commercially available and readily
aggregates in aqueous solution [34]. Since soluble Ab42 oligomers
are believed to be the pathogenic peptides responsible for synaptic
changes [36], we first ensured that oligomers were indeed present
in our preparations, examining the aggregation state of Ab42 by
Western blotting. Oligomeric as well as monomeric Ab42 species
were consistently detected (fig. 1b). We then established the
optimum conditions that would allow detection of the peptide via
immuno-labelling and also ensure optimum survival of the
neurons, applying different concentrations of Ab42 to mature
(21 DIV) dissociated hippocampal neurons.
Our results showed that incubation of dissociated hippocampal
neurons with 50 nM of Ab42 for 20 min, followed by recovery
periods of 15 min, 2 hrs and 4 hrs allowed both, detection of
Ab42 and optimum survival of neurons. To look into the dynamics
of the internalisation of Ab42, sequential immuno-labelling of
fixed neurons (treated with 50 nM of Ab42) was employed to
distinguish between surface and internalised Ab42. Surface
labelling was carried out using the 6E10 primary antibody (for
Ab detection) and the Alexa-Fluor 488 secondary antibody in the
absence of detergent. The neurons were then post fixed and
intracellular Ab42 was detected by repeating the procedure using
the same primary antibody and the Alexa-Fluor 555 secondary
antibody in the presence of 0.1% Tween-20 to permeabilise the
cells. After 15 min of recovery, a high degree of co-labelling was
observed, suggesting the peptide remained extracellular (fig. 2a).
However, with increased recovery time, although co-labelling was
still evident, additional signal was increasingly observed after
permeabilisation (fig. 2b, c) showing that after 2 hrs of recovery
Ab42 had been internalised. To quantify the extent of the
internalisation, the co-localisation was quantified by calculating
the split Mander’s co-localisation coefficients using the JACoP
plugin for Image-J [39]. Mander’s co-efficient measures the
coincidence of two signals, even when the intensities in both
channels are significantly different. Our results (fig. 2d) show that
the Mander’s coefficient was highest (0.9260.7 n= 6) after the
15 min recovery time point, suggesting a high degree of co-
localisation. Within a 2 hrs recovery period, the Mander’s
coefficient dropped significantly (0.6460.07 n = 10, student t-test
p = 0.0006). Similarly, after 4 hrs of recovery, the Mander’s
coefficient was lower than the 15 min recovery period
(0.7060.08 n = 8, student t-test p = 0.0021) confirming our observa-
tion that Ab42 can be detected intracellularly over a 4 h period
[40].
Presynaptic Localisation of Ab42
Since we identified Syp as a possible interacting partner of
Ab42, we examined if such an interaction could mediate the
internalisation/endocytosis of Ab42 at synaptic contacts. Dissoci-
ated neurons were incubated with Ab42 (50 nM) for 20 min and
allowed to recover in fresh media for 15 min or 2 hrs prior to
fixation. If Ab42 was internalised via its interaction with Syp, we
would expect Ab42 to be localised at presynaptic terminals soon
after incubation with the peptide. Double immuno-labelling for
Ab42 and Syp after 15 min of recovery, did not reveal any
significant overlap between Ab42 and presynaptic contacts
marked by Syp labelling (fig. 3a, n= 15). On the contrary, Ab
labelling was often detected juxtaposed to Syp (arrow in high
magnification of fig. 3a) suggesting a postsynaptic localisation of
Ab [11,41]. After 2 hrs of recovery however, co-localisation
between Ab42 and Syp labelling in a fraction of synapses was
evident (fig. 3b, n = 39). These results showed that although
internalisation of Ab42 via an interaction with Syp is unlikely, the
peptide can be detected pre-synaptically after an extended period
of time. To further confirm our findings, we repeated the
experiment using VAMP2 as an alternative presynaptic marker.
Figure 4. Disruption of the Syp/VAMP2 complex. (a) Immunoprecipitation of VAMP2 from hippocampal extracts assayed by western blotting
for VAMP2 and Syp. A band of 19 kDa corresponding to VAMP2 and a band of 38 kDa, corresponding to Syp were detected in all conditions. A
reduction in immunoprecipitated Syp was induced by Ab42 (lane 3) compared to control (scrambled Ab, lane 4). (b) The intensity ratio between Syp
and VAMP2 is reduced in the presence of Ab42 (n = 3, student t-test p = 0.0026). (c) co-labelling for Syp and VAMP2 in untreated hippocampal
neurons, in neurons treated either with Ab42 and allowed to recover for 15 min (d) or with scrambled peptide (f) display a significant degree of co-
localisation. (e) Ab42 treated neurons allowed to recover for 2 hrs display stretches of VAMP2 immunoreactivity (indicated by arrows). (g)
Quantification of the extent of co-localisation between Syp and VAMP2. Ab42 treated neurons left to recover for 2 hrs showed decreased level of co-
localisation (M=0.8560.09, n = 24) compared to control (M= 0.96160.03, n = 24, student t-test ** = 0.0003), whereas neurons left to recover for
15 min (M=0.9960.02, n = 24) or incubated with the scrambled peptide (M= 0.9960.01, n = 18) did not display differences compared to control.
Scale bar = 10 mm.
doi:10.1371/journal.pone.0043201.g004
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Similar to our previous observations, after 15 min of recovery no
overlapping pattern between Ab42 and VAMP2 labelling was
evident (fig. 3c, n= 15), whereas after 2 hrs of recovery, co-
localisation between VAMP2 and Ab42 could be detected (fig. 3d,
n = 39), further confirming its presence at pre-synaptic terminals.
However, compared to Syp, the pattern of VAMP2 staining after
2 hrs of recovery was unusual, with visible stretches along the
membrane (see brackets in high magnification of fig. 3d) instead of
the characteristic punctate pattern (fig. 3c). Finally, double
immuno-labelling for Ab42 and NMDARs in dissociated neurons
incubated with 50 nM of Ab42 for 20 min and allowed to recover
in fresh media for 2 hrs prior to fixation showed that Ab42 could
be detected alongside as well as juxtaposed to NMDARs
confirming its presynaptic localisation (arrows in fig. 3e). However,
these data were unexpected since previous reports have demon-
strated that incubation of dissociated neurons with Ab peptides
results in its postsynaptic localisation [11,41,42]. Since neuro-
transmitter release has been associated with a rapid increase in the
extracellular levels of Ab42 [43], we considered the possibility that
the observed presynaptic localisation of Ab42 could be transient,
followed by its release into the synaptic cleft in an activity
dependent manner. Subsequently the released Ab42 would
interact with postsynaptic targets. To test this hypothesis,
dissociated hippocampal neurons exposed to 50 nM of Ab were
depolarised after 2 hrs of recovery. The neurons were treated with
50 mM KCl for 10 min to induce neurotransmitter release.
Double immuno-labelling for Ab42 and NMDARs showed that
a substantial amount of Ab42 was still juxtaposed to, NMDARs
(fig. 3f). Quantification of the extent of co-localization between Ab
and NMDARs by calculating the Mander’s co-efficient, did not
reveal any statistically significant differences between neurons
exposed to Ab42 (0.29660.05) and neurons exposed to Ab42 and
depolarised after recovery (0.34860.03, student t-test p = 0.098,
n = 10). These results suggest that the presynaptic localisation of
Ab42 was not transient since a substantial amount of the peptide
remained presynaptic even after induction of neuronal activity.
Ab42 Disrupts the Syp/VAMP2 Complex
The biochemical interaction of Ab42 with Syp and its presence
at the presynaptic terminal suggests that the peptide may have
a pre-synaptic effect. To explore this further, we looked closer at
the unusual distribution of VAMP2 in neurons exposed to Ab42
(high magnification of fig. 3 d). It has been shown that Syp
interacts with VAMP2 regulating its synaptic distribution [44].
Thus we hypothesised that the diffuse distribution of VAMP2
could be a consequence of Ab42 interfering with the formation of
the VAMP2/Syp complex. To test this, we immunoprecipitated
VAMP2 complexes from hippocampal extracts either in the
presence of an excess of Ab42, or in the presence of a similar
concentration of control, scrambled Ab (fig. 4a). A substantial
reduction of co-immunoprecipitated Syp was observed in the
presence of Ab42 (fig. 4b, n= 3), compared to the amount of co-
immunoprecipitated Syp in the presence of the scrambled peptide
suggesting that Ab42 disrupts the interaction between VAMP2
and Syp in vitro.
Since it has been shown that disruption of the interaction
between VAMP2 and Syp induces the axonal distribution of
VAMP2 [44], we compared the extent of co-localisation between
these two proteins in neurons exposed to Ab42 and control
neurons to investigate if Ab42 disrupts their interaction in living
neurons as well. Double immuno-labelling of VAMP2 and Syp in
control neurons (fig. 4c) and in neurons recovering for 15 min
after exposure to 50 nM of Ab42 (fig. 4d) showed the expected
extensive co-localisation between the two proteins suggesting that
Ab42 had little or no effect on the VAMP2-Syp complex during
the first 15 min of recovery. On the contrary, VAMP2 labelling in
neurons exposed to Ab42 after 2 hrs of recovery (fig. 4e) showed
stretches of VAMP2 immunoreactivity devoid of Syp labelling (i.e.
areas between arrows in figure 4e). This diffuse VAMP2 labelling
is indicative of a disruption in the formation of the VAMP2/Syp
complex in vivo [44] demonstrating that Ab42 interferes with the
stability of the interaction between VAMP2 and Syp. The co-
localisation of VAMP2 and Syp was not affected in neurons
exposed to similar concentration of the scrambled peptide (fig. 4f)
suggesting the diffuse VAMP2 labelling is specifically induced by
Ab42 and not by the addition of any non specific peptide in the
medium. Quantification of the extent of co-localisation between
Vamp and Syp, by calculating the Mander’s co-efficient,
confirmed that their co-localisation was specifically reduced in
neurons exposed to Ab42 and allowed to recover for 2 hrs (fig. 4g).
Physiological Consequences in Synaptic Transmission
Further to its role in sorting VAMP2, Syp also interacts with
VAMP2 at the presynaptic terminal and it has been proposed that
it regulates the participation of VAMP2 in the SNARE complex
during the formation of the fusion pore complex (FPC) [45,46,47].
Therefore, disruption of the association between VAMP2 and Syp
at synaptic contacts by Ab42 could induce the formation of the
FPC resulting in an increase of primed SVs. To investigate this
hypothesis, untreated mature hippocampal neurons or neurons
treated for 15 min either with 50 nM of Ab42 or with the inverted
control peptide, were incubated after 2 hrs of recovery with FM1-
43 FX, a fluorescent lipophilic dye that labels membranes. Using
a hypertonic sucrose solution (500 mM sucrose in HBSS) primed
vesicles were induced to fuse to the presynaptic membrane and
neurons were left to recover in the presence of the dye to allow for
its uptake at sites of SV recycling [48]. Incorporation of the dye at
synaptic contacts was confirmed with immuno-labelling for Syp.
Images of mature (21 DIV) untreated hippocampal neurons
(fig. 5a) and neurons treated either with scrambled peptide as
a negative control (fig. 5b) or with Ab42 (fig. 5c) were taken
consecutively leaving the microscope/camera settings unaltered.
In untreated neurons or in neurons exposed to the control inverted
peptide, uptake of the dye at synaptic contacts was near
background levels, although internalisation of the dye was evident
in the cell soma (n = 20, fig. 5 a, b). On the contrary, in neurons
exposed to Ab42, the dye uptake was more pronounced at
a fraction of synaptic contacts (fig. 5c, n= 20), indicative of an
increase in the number of vesicles primed to the presynaptic
membrane. These results strongly suggest that Ab42 increases the
amount of primed vesicles at the presynaptic terminal. The
question now was if this increase would contribute to synaptic
transmission. Although our results show that Ab42 could be
detected at the presynapse via immuno-labelling after 2 hrs of
Figure 5. Fusion of primed vesicles at synaptic contacts marked by labelling for Syp (green) is visualised by the extent of
internalisation of FM1-43FX dye (red). High magnification images of boxed areas are shown on the right. Internalised dye at synapses is near
background levels in untreated (n = 20) (a) as well as in neurons treated with the scrambled peptide (n = 20) (b). Arrows in a and b point at synaptic
contacts labelled with Syp. (c) Exposure to Ab42 followed by 2 hrs of recovery results in a significant increase in internalised dye at synaptic contacts
(n = 20). Arrows in c point at synaptic contacts labelled with Syp. Scale bar = 10 mm.
doi:10.1371/journal.pone.0043201.g005
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recovery, it has been demonstrated that incubation of slices with
Ab42 for a shorter period of time, is necessary and sufficient to
induce detectable synaptic defects [19,49]. To account for possible
differences in the physiology of neurons between hippocampal
slices and dissociated neurons, we adopted a similar approach to
investigate the effect of Ab42 on synaptic transmission. Consistent
Figure 6. Neurotrasmitter release is affected by Ab. (a) Induction of CA1- LTP after HFS in control hippocampal slices (Two-way ANOVA
p= 0.0006 n= 5). (b) Induction of CA1-LTP after HFS is blocked in hippocampal slices after a 45 min bath application of Ab42. (c) fEPSPs recorded in
the CA1 in response to a 50 V stimulus of the Schaffer collateral commissural pathway showed a concentration dependent effect of Ab in fEPSPs.
Only mid-range concentrations of 0.3 nM and 1 nM were able to increase the fEPSP slope (p = 0.028 and p= 0.048 respectively with student t-test,
n = 5 for each concentration tested). (d) Treatment with Ab42 (45 min) increases the stimulation response compared to control, untreated slices over
a range of stimuli. Results are presented as the percentage of the maximum fEPSP from control recordings (n$5 each). Inlet in shows a trace of EPSP
slopes between a control slice and a slice treated with Ab42 stimulated at 50 V. (e) Chelation of Ab42 using 6E10, a specific antibody for the peptide,
abrogates the enhancement at all input values (n = 5). (f) Scrambled Ab did not induce increased responses compared to controls.
doi:10.1371/journal.pone.0043201.g006
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Figure 7. ELISA assay from fractionated conditioned media (CM) from 7PA2 cells and control CHO cells detected Ab oligomers in
the conditioned medium of 7PA2 cells but not of CHO control cells (a). Hippocampal slices were incubated with CM from fractions 12, 24
and 36 of control as well as 7PA2 cells. fEPSPs were recorded in response to Schaffer collateral commissural pathway stimulation at a range of
stimulus from 10 V through to 60 V (b and d). Incubation with cell-derived Ab, increased the response to stimulation at the CA1 synapse (b).
compared to slices treated with conditioned media from the control CHO cells (d). The results are expressed as a percentage of the maximum fEPSP
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with previous studies, hippocampal slices incubated with Ab42 for
45 min prior to recording showed that Ab42 inhibited the
induction of NMDAR-dependent LTP in the hippocampal CA1
region (fig. 6a, b). Next, we investigated if under the same
conditions Ab42 affected basal transmission. We compared
fEPSPs recorded from the CA1 region of hippocampal slices in
response to electrical stimulation of the Schaffer collateral
pathway, in the presence or absence of Ab42. First, we noticed
a concentration dependent enhancement in basic transmission at
concentrations ranging from 300 pM to 1 nM Ab42 (fig. 6c). We
subsequently investigated this effect in detail by increasing
electrical stimulation in slices exposed to 1 nM Ab42. Our results
showed a progressive enhancement of fEPSPs recorded in treated
slices compared to untreated control slices (fig. 6d, p= 0.044 at
50 V with student’s t-test, n = 5), indicative of an increased efficacy
of the Schaffer collateral synapse. We then confirmed the
specificity of this enhanced efficacy either by chelation of Ab42
using an excess of an Ab42 specific antibody (200 ng/ml of 6E10
mAb), or by using equal concentrations of the scrambled peptide.
Co-incubation with 6E10 and Ab42 produced similar recordings
to untreated slices (fig. 6e, n= 5). Furthermore, incubation of slices
with the scrambled peptide had no effect (fig. 6f, n = 5) further
confirming that the enhancement of fEPSPs was specific to Ab42.
To unambiguously confirm that the enhancement of synaptic
transmission was induced by Ab, we repeated our experiments
with cell-derived Ab peptides, from 7PA2 cells, These Chinese-
hamster ovary cells that express the V717F mutant human APP
secrete low (nanomolar) levels of oligomeric Ab peptides [35,50].
Incubation of slices with cell derived oligomers provided similar
results to those obtained with the synthetic peptide, suggesting that
the enhancement of fEPSPs is not an artefact of the synthetic
peptide (Fig. 7) but rather a physiological function of Ab.
Discussion
Synaptic Localisation of Ab42
Whilst extensive information in the literature shows that
synaptic failure precedes cognitive decline in AD [4] the cellular
and molecular events underlying this synaptic dysfunction are still
not fully resolved. The data presented here provide an insight into
one mechanism by which Ab42 affects synaptic activity. First, we
show that the presynaptic protein Syp interacts with Ab42 in vitro.
We then establish the significance of this interaction by showing
that Syp and externally applied Ab42 can co-localise in living
neurons. Studies with transgenic animal models of AD, have
supported the presence of intraneuronal Ab (iAb) prior to the
appearance of extracellular deposits, suggesting that iAb is
a significant contributor to the onset of learning and memory
deficits [38,51]. Despite an apparent relationship between the
intracellular pool of Ab and the extracellular deposits [13,52] the
precise mechanism by which the peptide enters the neuron is still
under investigation. Physical interaction between Ab42 and the a7
acetylcholine receptor [53] or apoE [54] suggests that these
proteins are candidates for a receptor mediated transfer of Ab into
the cell. On the other hand, there is evidence that Ab peptides
cross the neuronal membrane passively, via non-endocytic and
energy independent pathways, most likely due to its ability to
biophysically interact with lipids at the neuronal membrane [55].
Thus, we considered the possibility that an interaction between
Syp and Ab42 at the presynaptic terminal could be an alternative
mechanism for its internalisation. We examined the dynamics of
the co-localisation of these proteins and found no evidence to
support the hypothesis that interaction of Ab42 with Syp provides
an alternative mechanism for the internalisation of the peptide,
since there was no indication of presynaptic localisation of Ab42 in
neurons that were left to recover for only 15 min. Interestingly
though, the absence of co-localisation at early time points
compared to the co-localisation we observed 2 hrs after the
removal of Ab from our cultures, shows that Ab42 can accumulate
at the presynaptic terminal with time. It is therefore likely that, at
least in part, the presynaptic localisation of Ab42 could be due to
its translocation at the presynaptic terminal by an unknown
transport mechanism. Co-labelling for Ab42 and NMDARs
further confirmed that Ab42 could be detected at presynaptic as
well as at postsynaptic terminals.
In contrast to the data presented here, several reports
demonstrate exclusive co-localisation between Ab42 and post-
synaptic markers [11,41]. In one such study, Lacor and colleagues
found 92% of exogenously applied Ab co-localised with the post-
synaptic protein PSD-95 and the majority of the peptide was
found juxtaposed to Syp [41]. We believe that the difference in our
results reflects differences in our experimental procedures. For
instance, a plausible explanation is that we allowed cells to recover
for two to four hours after exposure to Ab42. This recovery period
(in the absence of the peptide) proved to be essential for the
detection of the peptide at presynaptic terminals. In addition,
Lacor et.al. showed that only high molecular weight species of Ab
peptides could be detected post-synaptically whereas our Ab
preparation was enriched in low oligomeric forms. We suggest that
taken together, these results complement each other, demonstrat-
ing two different roles of Ab at the synapse, one presyanptic and
the other postsynaptic.
Mechanism of Synaptic Toxicity
Confusing data regarding the effect of Ab42 in synaptic
dysfunction such as increase or suppression of spontaneous activity
are often found in the literature [56,57]. The underlying problem
in resolving these inconsistencies has been to understand the
mechanisms by which differences in the amount/preparation of
the peptides can affect the outcome of an experiment. Further-
more, the ambiguousness of the causal mechanisms behind these
effects has further challenged consistent interpretation of these
data. We believe that our findings regarding the presynaptic
localisation, the interaction between Ab42 and Syp and its effect in
neurotransmitter release may help resolve some of these incon-
sistencies. Syp was the first SV protein to be characterised [58,59].
Since then, various studies have implicated Syp in exocytosis, in
regulating the formation of the fusion pore complex (FPC), in
synapse formation and in endocytosis of SVs
[45,46,47,60,61,62,63]. However, studies using Syp KO mice
failed to show an apparent SV recycling phenotype [64,65]. The
lack of an obvious phenotype was attributed to the redundant
function of its isoforms Synaptogyrin (syg) and Synaptoporin.
Indeed, mice lacking both Syp and Syg expression showed
reduced LTP [66] although the mechanism responsible for this
reduction is still not clear.
One of the best characterised roles of Syp is its interaction with
VAMP2 [45], a SNARE protein [67]. The complex between
slope from control slices. Graphs showing representative results at 50 V in slices exposed to 7 PA conditioned medium (c) and to control CHO
conditioned medium (e) show that cell derived Ab increased fEPSP (student’s t-test p = 0.003 n= 5), whereas the control medium had no affect at
50 V (n = 5) (e).
doi:10.1371/journal.pone.0043201.g007
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VAMP2 and Syp is formed at the trans-Golgi network (TGN), and
the formation of this complex is necessary and sufficient to recruit
VAMP2 to synaptic contacts. Disruption of this interaction results
in diffuse localisation of VAMP2 along the axonal membrane [44].
Here we demonstrate that Ab42 disrupts the interaction between
VAMP2 and Syp both in vitro and in dissociated neurons (fig. 4).
Two possible mechanisms could account for this disruption: either
Ab42 disrupts a signalling pathway that regulates the dynamics of
this interaction at the TGN, or it competes with VAMP2 for
binding to Syp. Our immunoprecipitation data demonstrate that
Ab42 directly competes with VAMP2 for binding to Syp
supporting the latter hypothesis. We also observed that this
disruption was more pronounced in less mature neurons (14 DIV)
when synapses are not yet fully mature and there is increased
traffic of structural components towards the developing synapses.
In addition to correctly sorting VAMP2 at the synapse, Syp also
regulates the retrieval kinetics of VAMP2 during endocytosis [63].
Thus, if Ab42 competes with VAMP2 for binding to Syp at the
synapse, it is likely that it will also affect SV recycling. Ab42
induced changes to SV recycling has previously been reported.
Kelly et.al. proposed that Ab disrupts SV endocytosis, a phenotype
consistent with reduced binding of Syp to VAMP2 in Ab treated
neurons [68]. Finally, it has also been reported that VAMP2
dissociates from Syp prior to exocytosis suggesting that Syp
prevents VAMP2 from participating in the formation of the FPC
[46,69]. Furthermore, it has also been shown that Ab induces an
extensive depletion of the SV pool, indicative of an increased
participation of SVs in neurotransmitter release [68]. Thus, we
hypothesised that disruption of the interaction between Syp and
VAMP2 would increase the availability of VAMP2, contributing
towards an increase in the number of primed vesicles at the
presynaptic membrane. We verified this by showing that fusion of
primed SV in the presence of FM1-43FX results in an increase of
endocytosed dye at the synapses of neurons incubated with Ab42.
In addition, the enhancement of single-shock fEPSPs by Ab42 in
synapses within hippocampal slices further suggested an increased
availability of releasable SVs. What is more, the same effect was
reproduced by naturally produced amyloid peptides demonstrat-
ing that this effect is independent of the peptide source. It is
important to note that we were also able to reproduce the well-
established disruption of LTP by Ab42 under the same
experimental conditions. In support of our results, several reports
have shown an Ab-dependent increase in the number of vesicles
available at the presynaptic active zone [19,28,70] or that
glutamate release is enhanced by Ab peptides [71]. These results
suggest that regulation of NT release at the pre-synaptic level
could be an important aspect of the physiological role of Ab.
Furthermore, increasing evidence suggests that Ab could exert its
effects in synaptic plasticity by excessive activation of NMDARs.
For instance, it has been shown that inhibition of LTP by Ab can
be via a mechanism involving excessive activation of extrasynaptic
NMDARs as well as due to defects in glutamate uptake [29,32,33].
A key question that remains to be answered though is to what
extent the interaction between Ab and Syp that we report here, is
necessary and sufficient to induce the observed increase in synaptic
transmission, or to what extent this interaction is a contributing
factor affecting the homeostasis of the presynaptic terminal.
Although our data clearly demonstrate that Ab is detected at the
presynapse where it can interact with Syp affecting neurotrans-
mitter release, its presynaptic effects are likely to be more complex.
For instance, it has been shown that Ab inhibits presynaptic P/Q
Ca channels suppressing spontaneous synaptic activity [57,72].
Interestingly, a series of studies demonstrated that Ab can also
have a positive effect on synaptic transmission in a concentration
dependent manner. It has been shown that picomolar concentra-
tions of Ab42 enhance neurotransmitter release during HFS [19]
and can also activate presynaptic a7-nAChRs [73]. Finally, Puzzo
et.al showed that newly formed endogenous Ab is essential for NT
release from the presynaptic terminal [74], demonstrating further
that at least in part, Ab exerts its function at the pre-synapseThe,
data presented here could contribute towards our understanding
of the mechanism behind these observations. It is possible that the
disruption of the Syp/VAMP2 complex contributes towards an
increase in NT release, allowing VAMP2 to participate more
readily in the formation of SNARE complexes deregulating NT
release by increasing the amount of primed SVs. Moreover,
following exocytosis, the ability of Syp to initiate SV endocytosis
via its interaction with VAMP2 [62,63] would be reduced. Such
a mechanism can explain both the positive contribution of Ab to
NT release as well as the reported disruption of endocytosis and
the depletion of SVs induced by Ab [19,68,74]. Furthermore our
data are also supported by findings that show a ‘‘bell shaped’’
relationship between Ab and synaptic plasticity [28]. Consequent-
ly, long term exposure and/or high levels of Ab42 would
consistently deregulate glutamate release, disrupting LTP
[33,68,70] and inducing excitotoxicity [75]. Finally, at later stages,
increased release of Ab42 from presynaptic sites [43] would induce
additional effects at the postsynaptic membrane.
An increasing number of reports in the past years demonstrate
that glutamatergic synaptic transmission via AMPA, NMDA and
metabotropic glutamate receptors is crucial in the pathogenesis of
AD. Targeting these receptors for AD therapy although beneficial
comes with side effects. Thus, understanding the cellular
mechanism behind the deregulation of glutamatergic neurotrans-
mission might provide alternative therapeutic targets. Further-
more, in a recent publication, Puzzo et.al. pointed out that
impairment of LTP at early stages of the disease is not necessarily
linked to interference with the function of AMPAR or NMDAR
and only increased concentrations of Ab or prolonged exposure to
the peptide showed a direct impairment of the receptors [25]. Our
data further support this observation since we showed that brief
exposure to Ab42 at concentrations that are not known to directly
interfere with the receptors, results in LTP impairment that is
likely induced by pre-synaptic defects. Taken together, these data
suggest that Ab42 is involved in modulation of synaptic activity by
interfering with multiple pre- and postsynaptic mechanisms in
a concentration and time dependent manner.
Although our data showed the effect of Ab42 on a cellular
mechanism that can contribute to the deregulation of glutama-
tergic synaptic transmission, it is quite possible that we have
demonstrated only one of several cellular events disrupted by Ab.
Nevertheless, our data make an important contribution in
elucidating the pleiotropic function of Ab. Understanding the
causative events behind its toxicity is essential in order to design
appropriate therapeutic strategies to target the symptoms of AD
more efficiently.
Acknowledgments
We would like to thank D.M. Walsh for providing the 7PA2 cell line.
Author Contributions
Conceived and designed the experiments: PA RME. Performed the
experiments: CLR SS. Analyzed the data: CLR SS RME PA. Contributed
reagents/materials/analysis tools: PA PWB BMA. Wrote the paper: PA.
Amyloid-Beta and Synaptic Activity
PLOS ONE | www.plosone.org 12 August 2012 | Volume 7 | Issue 8 | e43201
References
1. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev
81: 741–766.
2. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking,
processing, and function. J Biol Chem 283: 29615–29619.
3. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology
of Alzheimer’s disease. Trends Pharmacol Sci 12: 383–388.
4. Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298: 789–791.
5. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, et al. (1997) Neuronal
loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease.
Ann Neurol 41: 17–24.
6. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific
amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352–
357.
7. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998)
Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central
nervous system neurotoxins. Proc Natl Acad Sci U S A 95: 6448–6453.
8. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005)
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive
function. Nat Neurosci 8: 79–84.
9. Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, et al. (2006)
Amyloid beta peptide adversely affects spine number and motility in
hippocampal neurons. Mol Cell Neurosci 33: 274–282.
10. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, et al. (2007)
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible
synapse loss by modulating an NMDA-type glutamate receptor-dependent
signaling pathway. J Neurosci 27: 2866–2875.
11. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, et al. (2007)
Abeta oligomer-induced aberrations in synapse composition, shape, and density
provide a molecular basis for loss of connectivity in Alzheimer’s disease.
J Neurosci 27: 796–807.
12. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. (2003) Triple-
transgenic model of Alzheimer’s disease with plaques and tangles: intracellular
Abeta and synaptic dysfunction. Neuron 39: 409–421.
13. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM (2006) A dynamic
relationship between intracellular and extracellular pools of Abeta. Am J Pathol
168: 184–194.
14. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, et al. (1999) Plaque-
independent disruption of neural circuits in Alzheimer’s disease mouse models.
Proc Natl Acad Sci U S A 96: 3228–3233.
15. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic
plasticity and behavior. Behav Brain Res 192: 106–113.
16. Hardy J (2009) The amyloid hypothesis for Alzheimer’s disease: a critical
reappraisal. J Neurochem 110: 1129–1134.
17. Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ (2001) Use-dependent
effects of amyloidogenic fragments of (beta)-amyloid precursor protein on
synaptic plasticity in rat hippocampus in vivo. J Neurosci 21: 1327–1333.
18. Cullen WK, Suh YH, Anwyl R, Rowan MJ (1997) Block of LTP in rat
hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport
8: 3213–3217.
19. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, et al. (2008) Picomolar
amyloid-beta positively modulates synaptic plasticity and memory in hippocam-
pus. J Neurosci 28: 14537–14545.
20. Harkany T, Abraham I, Timmerman W, Laskay G, Toth B, et al. (2000) beta-
amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade
in rat nucleus basalis. Eur J Neurosci 12: 2735–2745.
21. Puangthong U, Hsiung GY (2009) Critical appraisal of the long-term impact of
memantine in treatment of moderate to severe Alzheimer’s disease. Neuropsy-
chiatr Dis Treat 5: 553–561.
22. Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li YS, et al. (2008)
Memantine leads to behavioral improvement and amyloid reduction in
Alzheimer’s-disease-model transgenic mice shown as by micromagnetic
resonance imaging. J Neurosci Res.
23. Klyubin I, Wang Q, Reed MN, Irving EA, Upton N, et al. (2011) Protection
against Abeta-mediated rapid disruption of synaptic plasticity and memory by
memantine. Neurobiol Aging 32: 614–623.
24. Molnar Z, Soos K, Lengyel I, Penke B, Szegedi V, et al. (2004) Enhancement of
NMDA responses by beta-amyloid peptides in the hippocampus in vivo.
Neuroreport 15: 1649–1652.
25. Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, et al. (2009)
Phosphodiesterase 5 inhibition improves synaptic function, memory, and
amyloid-beta load in an Alzheimer’s disease mouse model. J Neurosci 29:
8075–8086.
26. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, et al. (2006) AMPAR
removal underlies Abeta-induced synaptic depression and dendritic spine loss.
Neuron 52: 831–843.
27. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, et al. (2005) Regulation of
NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8: 1051–1058.
28. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, et al. (2009) Amyloid-
beta as a positive endogenous regulator of release probability at hippocampal
synapses. Nat Neurosci 12: 1567–1576.
29. Harris ME, Carney JM, Cole PS, Hensley K, Howard BJ, et al. (1995) beta-
Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate
uptake in cultured astrocytes: implications for Alzheimer’s disease. Neuroreport
6: 1875–1879.
30. Arias C, Arrieta I, Tapia R (1995) beta-Amyloid peptide fragment 25–35
potentiates the calcium-dependent release of excitatory amino acids from
depolarized hippocampal slices. J Neurosci Res 41: 561–566.
31. Kabogo D, Rauw G, Amritraj A, Baker G, Kar S (2008) beta-Amyloid-related
peptides potentiate K+-evoked glutamate release from adult rat hippocampal
slices. Neurobiol Aging 31: 1164–1172.
32. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, et al. (2009) Soluble
oligomers of amyloid Beta protein facilitate hippocampal long-term depression
by disrupting neuronal glutamate uptake. Neuron 62: 788–801.
33. Li S, Jin MB, Koeglsperger T, Shepardson NE, Shankar GM, et al. (2011)
Soluble Ab Oligomers Inhibit Long-Term Potentiation through a Mechanism
Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA
Receptors. J Neuroscience 31: 6627–6638.
34. El-Agnaf OM, Mahil DS, Patel BP, Austen BM (2000) Oligomerization and
toxicity of beta-amyloid-42 implicated in Alzheimer’s disease. Biochem Biophys
Res Commun 273: 1003–1007.
35. Podlisny MB, Walsh DM, Amarante P, Ostaszewski BL, Stimson ER, et al.
(1998) Oligomerization of endogenous and synthetic amyloid beta-protein at
nanomolar levels in cell culture and stabilization of monomer by Congo red.
Biochemistry 37: 3602–3611.
36. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of
secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity:
a potent role for trimers. J Physiol 572: 477–492.
37. Sian AK, Frears ER, El-Agnaf OM, Patel BP, Manca MF, et al. (2000)
Oligomerization of beta-amyloid of the Alzheimer’s and the Dutch-cerebral-
haemorrhage types. Biochem J 349: 299–308.
38. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in
Alzheimer’s disease. Nat Rev Neurosci 8: 499–509.
39. Bolte S, Cordelieres FP (2006) A guided tour into subcellular colocalization
analysis in light microscopy. J Microsc 224: 213–232.
40. Saavedra L, Mohamed A, Ma V, Kar S, de Chaves EP (2007) Internalization of
beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. J
Biol Chem 282: 35722–35732.
41. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, et al. (2004) Synaptic
targeting by Alzheimer’s-related amyloid beta oligomers. J Neurosci 24: 10191–
10200.
42. Pellistri F, Bucciantini M, Relini A, Nosi D, Gliozzi A, et al. (2008) Non-specific
interaction of prefibrillar amyloid aggregates with NMDA and AMPA receptors
results in Ca2+ increase in primary neuronal cells. J Biol Chem.
43. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, et al. (2005) Synaptic
activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48: 913–
922.
44. Pennuto M, Bonanomi D, Benfenati F, Valtorta F (2003) Synaptophysin I
controls the targeting of VAMP2/synaptobrevin II to synaptic vesicles. Mol Biol
Cell 14: 4909–4919.
45. Calakos N, Scheller RH (1994) Vesicle-associated membrane protein and
synaptophysin are associated on the synaptic vesicle. J Biol Chem 269: 24534–
24537.
46. Pennuto M, Dunlap D, Contestabile A, Benfenati F, Valtorta F (2002)
Fluorescence resonance energy transfer detection of synaptophysin I and
vesicle-associated membrane protein 2 interactions during exocytosis from single
live synapses. Mol Biol Cell 13: 2706–2717.
47. Arthur CP, Stowell MH (2007) Structure of synaptophysin: a hexameric
MARVEL-domain channel protein. Structure 15: 707–714.
48. Gaffield MA, Betz WJ (2006) Imaging synaptic vesicle exocytosis and
endocytosis with FM dyes. Nat Protoc 1: 2916–2921.
49. Wang Q, Rowan MJ, Anwyl R (2004) Beta-amyloid-mediated inhibition of
NMDA receptor-dependent long-term potentiation induction involves activation
of microglia and stimulation of inducible nitric oxide synthase and superoxide.
J Neurosci 24: 6049–6056.
50. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, et al. (1995)
Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable
oligomers in cell culture. J Biol Chem 270: 9564–9570.
51. Li M, Chen L, Lee DH, Yu LC, Zhang Y (2007) The role of intracellular
amyloid beta in Alzheimer’s disease. Prog Neurobiol 83: 131–139.
52. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta
immunotherapy leads to clearance of early, but not late, hyperphosphorylated
tau aggregates via the proteasome. Neuron 43: 321–332.
53. Nagele RG, D’Andrea MR, Anderson WJ, Wang HY (2002) Intracellular
accumulation of beta-amyloid(1–42) in neurons is facilitated by the alpha 7
nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience 110: 199–
211.
54. Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, et al. (2006)
Apolipoprotein E and low density lipoprotein receptor-related protein facilitate
intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem 281:
36180–36186.
Amyloid-Beta and Synaptic Activity
PLOS ONE | www.plosone.org 13 August 2012 | Volume 7 | Issue 8 | e43201
55. Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF (2009)
Mechanism of neuronal versus endothelial cell uptake of Alzheimer’s disease
amyloid beta protein. PLoS ONE 4: e4627.
56. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, et al. (1999) Protofibrillar
intermediates of amyloid beta-protein induce acute electrophysiological changes
and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876–8884.
57. Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, et al. (2008)
Amyloid beta oligomers (A beta(1–42) globulomer) suppress spontaneous
synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci 28:
788–797.
58. Leube RE, Kaiser P, Seiter A, Zimbelmann R, Franke WW, et al. (1987)
Synaptophysin: molecular organization and mRNA expression as determined
from cloned cDNA. Embo J 6: 3261–3268.
59. Wiedenmann B, Franke WW (1985) Identification and localization of
synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic
of presynaptic vesicles. Cell 41: 1017–1028.
60. Cameron PL, Sudhof TC, Jahn R, De Camilli P (1991) Colocalization of
synaptophysin with transferrin receptors: implications for synaptic vesicle
biogenesis. J Cell Biol 115: 151–164.
61. Spiwoks-Becker I, Vollrath L, Seeliger MW, Jaissle G, Eshkind LG, et al. (2001)
Synaptic vesicle alterations in rod photoreceptors of synaptophysin-deficient
mice. Neuroscience 107: 127–142.
62. Kwon SE, Chapman ER (2011) Synaptophysin regulates the kinetics of synaptic
vesicle endocytosis in central neurons. Neuron 70: 847–854.
63. Gordon SL, Leube RE, Cousin MA (2011) Synaptophysin Is Required for
Synaptobrevin Retrieval during Synaptic Vesicle Endocytosis. J Neurosci 31:
14032–14036.
64. Eshkind LG, Leube RE (1995) Mice lacking synaptophysin reproduce and form
typical synaptic vesicles. Cell Tissue Res 282: 423–433.
65. McMahon HT, Bolshakov VY, Janz R, Hammer RE, Siegelbaum SA, et al.
(1996) Synaptophysin, a major synaptic vesicle protein, is not essential for
neurotransmitter release. Proc Natl Acad Sci U S A 93: 4760–4764.
66. Janz R, Sudhof TC, Hammer RE, Unni V, Siegelbaum SA, et al. (1999)
Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I.
Neuron 24: 687–700.
67. Sollner T, Whiteheart SW, Brunner M, Erdjument-Bromage H, Geromanos S,
et al. (1993) SNAP receptors implicated in vesicle targeting and fusion. Nature
362: 318–324.
68. Kelly BL, Ferreira A (2007) Beta-amyloid disrupted synaptic vesicle endocytosis
in cultured hippocampal neurons. Neuroscience 147: 60–70.
69. Edelmann L, Hanson PI, Chapman ER, Jahn R (1995) Synaptobrevin binding
to synaptophysin: a potential mechanism for controlling the exocytotic fusion
machine. Embo J 14: 224–231.
70. Parodi J, Sepulveda FJ, Roa J, Opazo C, Inestrosa NC, et al. (2010) Beta-
amyloid causes depletion of synaptic vesicles leading to neurotransmission
failure. J Biol Chem 285: 2506–2514.
71. Cuevas ME, Haensgen H, Sepulveda FJ, Zegers G, Roa J, et al. (2011) Soluble
Abeta1–40 Peptide Increases Excitatory Neurotransmission and Induces
Epileptiform Activity in Hippocampal Neurons. J Alzheimers Dis.
72. Mezler M, Barghorn S, Schoemaker H, Gross G, Nimmrich V (2011) Abeta
oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes.
Br J Pharmacol.
73. Dougherty JJ, Wu J, Nichols RA (2003) Beta-amyloid regulation of presynaptic
nicotinic receptors in rat hippocampus and neocortex. J Neurosci 23: 6740–
6747.
74. Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, et al. (2011)
Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and
memory. Ann Neurol 69: 819–830.
75. Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and
neurodegeneration in Alzheimer’s disease. Neurochem Int 45: 583–595.
Amyloid-Beta and Synaptic Activity
PLOS ONE | www.plosone.org 14 August 2012 | Volume 7 | Issue 8 | e43201
